New Zealand markets close in 6 hours 28 minutes

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
65.95-0.12 (-0.18%)
At close: 04:00PM EDT
65.90 -0.05 (-0.08%)
After hours: 07:26PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close66.07
Bid64.26 x 2900
Ask66.26 x 1300
Day's range64.07 - 65.96
52-week range53.63 - 71.70
Avg. volume7,019,755
Market cap204.375B
Beta (5Y monthly)0.12
PE ratio (TTM)N/A
EPS (TTM)-0.36
Earnings dateN/A
Forward dividend & yield1.44 (2.17%)
Ex-dividend date24 Feb 2022
1y target est71.80
  • Zacks

    Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know

    Astrazeneca (AZN) closed at $65.95 in the latest trading session, marking a -0.18% move from the prior day.

  • Business Wire

    AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combinations in Patients With Liver and Biliary Tract Cancers

    WILMINGTON, Del., July 01, 2022--AstraZeneca presented data for IMFINZI® (durvalumab) combinations from the HIMALAYA and TOPAZ-1 Phase III trials at the European Association for the Study of the Liver's International Liver Congress 2022 (EASL 2022) and the European Society for Medical Oncology’s World Congress on Gastrointestinal Cancer (ESMO World GI 2022).

  • Financial Times

    Oxford BioMedica extends Covid vaccine deal with AstraZeneca

    Oxford BioMedica has extended its partnership with AstraZeneca, agreeing a new three-year contract to manufacture Covid-19 vaccines if the UK drugmaker presses on with mass production of the jab. The specialist pharmaceutical manufacturer, which also makes cell and gene therapies, will make its Oxbox facility available on an “as needed” basis to AstraZeneca after 2022. The original contract signed in September 2020 is expected to complete in the last quarter of this year, with Oxford BioMedica recognising roughly £30mn from AstraZeneca this financial year.